Reports for APOTEX INC
Formerly known as AA PHARMA INC
Company Name
APOTEX INC
Shortage reports
Actual shortage:
220 (7%)
Anticipated shortage:
0 (0%)
Avoided shortage:
10 (0%)
Resolved:
3124 (93%)
3354
Discontinuation Reports
To be discontinued:
26 (7%)
Discontinued:
343 (93%)
Reversed:
0 (0%)
369
145 (4%)
73 (30%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-NAPRO-NA | 275MG | TABLET | Resolved | 2022-06-06 | 2022-08-22 | 162077 |
| APO-NAPRO-NA DS | 550MG | TABLET | Resolved | 2019-01-03 | 2019-02-08 | 71139 |
| APO-NAPRO-NA DS | 550MG | TABLET | Resolved | 2022-07-15 | 2022-08-24 | 164744 |
| APO-NAPRO-NA DS | 550MG | TABLET | Resolved | 2023-05-26 | 2023-07-27 | 193215 |
| APO-NAPRO-NA DS TAB 550MG | 550MG | TABLET | Resolved | 2017-05-24 | 2018-10-05 | 11082 |
| APO-NAPROXEN | 250MG | TABLET | Resolved | 2018-08-09 | 2018-10-26 | 57799 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2025-01-23 | 2025-03-14 | 248489 |
| APO-NAPROXEN | 250MG | TABLET | Resolved | 2018-12-12 | 2018-12-21 | 69305 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2023-08-04 | 2023-08-12 | 201171 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2024-09-12 | 2024-11-15 | 237375 |
| APO-NAPROXEN | 250MG | TABLET | Resolved | 2020-02-13 | 2020-02-28 | 106003 |
| APO-NAPROXEN | 250MG | TABLET | Resolved | 2018-02-01 | 2018-04-05 | 37971 |
| APO-NAPROXEN | 375MG | TABLET | Resolved | 2023-09-07 | 2023-10-13 | 203849 |
| APO-NAPROXEN | 375MG | TABLET | Resolved | 2021-02-19 | 2021-03-17 | 134439 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2020-08-06 | 2020-10-05 | 121909 |
| APO-NAPROXEN | 375MG | TABLET | Resolved | 2020-01-22 | 2020-02-21 | 103914 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2021-04-05 | 2021-05-03 | 136805 |
| APO-NAPROXEN | 250MG | TABLET | Resolved | 2022-10-21 | 2022-11-11 | 172342 |
| APO-NAPROXEN | 375MG | TABLET | Resolved | 2018-12-12 | 2018-12-21 | 69312 |
| APO-NAPROXEN | 375MG | TABLET | Resolved | 2020-02-05 | 2020-02-21 | 105352 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-HYDROMORPHONE CR | 4.5MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110974 |
| APO-HYDROMORPHONE CR | 18MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110965 |
| APO-HYDROMORPHONE CR | 3MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110956 |
| APO-HYDROMORPHONE CR | 6MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110959 |
| APO-HYDROMORPHONE CR | 12MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110962 |
| APO-HYDROMORPHONE CR | 9MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110977 |
| APO-HYDROXYQUINE | 200MG | TABLET | Discontinued | 2018-09-07 | 2018-10-05 | 60524 |
| APO-IMIQUIMOD | Discontinued | 2019-11-26 | 2019-11-26 | 99672 | ||
| APO-IRBESARTAN | 150MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60536 |
| APO-IRBESARTAN | 150MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71234 |
| APO-IRBESARTAN | 75MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71231 |
| APO-IRBESARTAN | 300MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71237 |
| APO-IRBESARTAN | 300MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60539 |
| APO-IRBESARTAN/HCTZ | Discontinued | 2018-09-07 | 2018-09-15 | 60548 | ||
| APO-IRBESARTAN/HCTZ | 25MG 300MG | TABLET | Discontinued | 2018-02-23 | 2018-09-15 | 40769 |
| APO-IRBESARTAN/HCTZ | 25MG 300MG | TABLET | Discontinued | 2018-02-23 | 2018-09-15 | 40766 |
| APO-IRBESARTAN/HCTZ | Discontinued | 2018-02-23 | 2018-07-17 | 40763 | ||
| APO-IRBESARTAN/HCTZ | 12.5MG 150MG | TABLET | Discontinued | 2018-02-23 | 2018-02-23 | 40757 |
| APO-IRBESARTAN/HCTZ | 12.5MG 150MG | TABLET | Discontinued | 2018-02-23 | 2018-07-17 | 40760 |
| APO-LAMIVUDINE | 150MG | TABLET | Discontinued | 2018-09-07 | 2019-07-13 | 60557 |